# Santo

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/santo

- Industry: Biotechnology
- Headquarters: Zhejiang, China
- Website: www.santobiopharma.com/
- Latest round: Angel (Oct 9, 2025)
- Investors on record: 1

## About

Santo Ltd. is a biotechnology company based in China and founded in the year 2023, specializing in innovative gene therapy solutions using advanced lentiviral vector technology aimed at in vivo applications.Santo Ltd. operates under the name Santo Biopharma, focusing on gene therapy development. The company is located in Zhejiang, China, and has engaged in 1 deal, with the most recent one occurring on October 9, 2025. The founder of the company has a history of involvement in the biotechnology sector, although specific details about previous ventures are not provided.Santo Biopharma specializes in innovative gene therapy solutions utilizing advanced lentiviral vector technology, specifically focusing on in vivo applications. The company's core offerings include the STLenti® 5G lentiviral vector platform, which enhances the precision and safety of gene delivery targeting specific tissues. In addition, Santo Biopharma offers scientific consulting, outreach activities, and research collaborations aimed at the healthcare sector. Their product pipeline addresses severe clinical needs in oncology, targeting conditions such as neurofibromas, meningiomas, and malignant mesotheliomas, with aspirations to serve a global market with urgent therapeutic needs.Revenue generation at Santo Biopharma is primarily structured around partnerships and collaborations with clinical institutions, pharmaceutical companies, and research organizations. The company engages in B2B transactions, providing its lentiviral vector technologies and related services to clients involved in drug development and clinical research. Specific pricing structures for services are tailored based on project nature and scale, ensuring flexibility to meet varying partner needs. While individual product pricing details are not disclosed, the flagship STLenti® platform and related services are integral to driving revenue through these strategic collaborations. Santo Biopharma's focus on addressing unmet medical needs positions it to capture market interest and demand, facilitating a steady flow of transactions aligned with client requirements.In October 2025, Santo Therapeutics raised an undisclosed amount of venture funding led by FIRHealth Capital. The funding will be utilized to advance gene therapy research, improve manufacturing processes, and prepare regulatory filings in China and the United States. Santo Biopharma plans to expand its market reach by targeting new geographic regions, focusing on areas with significant healthcare demands as part of its growth strategy.

## Funding rounds

- Angel, Oct 9, 2025 — FIRHealth Capital

## Investors

- FIRHealth Capital (https://capitalatlas.ai/funds/firhealth-capital) — Angel